U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated
Oakwood Hospital - Southshore	July 18, 2014, 3. License No. 21-16656-01
1. Oakwood Hospital - Sodinshore	is amended in its entirety to read as follows:
2. 5450 Fort Street	4. Expiration Date: September 30, 2021
Trenton, Michigan 48183	5. Docket No. 030-11427 Reference No.
Byproduct, source, and/or special nuclear material 7. Chemical and/or special	7 or physical form 8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material A. Any permitted by 10 CFR 35.100	A. As needed
B. Any byproduct material B. Any permitted by 10 CFR 35.200	B. As needed
C. Any byproduct material C. Any permitted by 10 CFR 35.300	C. 500 millicuries
10 CFR 35.400 (SourceT	Sources (seeds) D. 1 curie Fech Medical, del STM 1251;
Internation	onal erapy, Inc.
10 CFR 35.400 (Therage	Sources (seeds) E. 1 curie enics Corp. 00; International
	erapy, Inc.

Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE 2 of 4 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License No. 21-16656-01	
	Docket or Reference No. 030-11427	
	Amendment No. 20	

D. and E. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

CONDITIONS

- 10. Licensed material may be used or stored at the licensee's facilities located at 5450 Fort Street, Trenton, Michigan.
- 11. A. The Radiation Safety Officer (RSO) for this license (except brachytherapy) is Michael Arsenault, D.O.
 - B. The Radiation Safety Officer (RSO) for this license for brachytherapy is Talgit Sandhu, Ph.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

Authorized User	Material and Use	
Sleman A. Khoury, M.D.	10 CFR 35.100, 35.200, and 35.30 oral administration of sodium iodide	•
Michael D. Arsenault, D.O.	10 CFR 35.100, 35.200, and 35.30 oral administration of sodium iodide	•
Ronald C. Lutsic, D.O.	10 CFR 35.300 and 35.400.	
Choon K. Lee, M.D.	10 CFR 35.400.	
Jung H. Chang, M.D.	10 CFR 35.400.	in the second se
Omar M. Salazar, M.D.	10 CFR 35.400.	
Nitin Vaishampayam, M.D.	10 CFR 35.400.	
Tai S. Kang, M.D.	10 CFR 35.100 and 35.200.	
Bruno F. Borin, D.O.	10 CFR 35.100 and 35.200.	
James J. Kochdodan, M.D.	10 CFR 35.100 and 35.200.	
Reza Abghari, M.D.	10 CFR 35.100 and 35.200.	
David S. Yates, M.D.	10 CFR 35.100 and 35.200.	
Gregory D. Olson, M.D.	10 CFR 35.100 and 35.200.	

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	3	of	4	PAGES
		License No. 21-16656-01					
MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference No. 030-11427						
		Amendment No. 20					

Authorized User	Material and Use
Jerry W. Drake, M.D.	10 CFR 35.100 and 35.200.
Kenneth D. Bartold, M.D.	10 CFR 35.100 and 35.200.
Dong Hyuck Kim, M.D.	10 CFR 35.100 and 35.200.
John H. Finger, M.D.	10 CFR 35.100 and 35.200.
Sophia Roumanis, M.D.	10 CFR 35.100 and 35.200.
Donald J. Conn, M.D.	10 CFR 35.100 and 35.200.
Rob Allen Reed, M.D.	10 CFR 35.100 and 35.200.
Vito A. Casano, M.D.	10 CFR 35.100 and 35.200.
Michael F. Zydeck, M.D.	10 CFR 35.100 and 35.200.
Jeffrey V. Tranchida, M.D.	10 CFR 35.100 and 35.200.
Vladislav Jankulov, M.D.	10 CFR 35.100 and 35.200.
Ashok B. Jain, M.D.	10 CFR 35.100 and 35.200.
Shakuntala B. Rao, M.D.	10 CFR 35.100 and 35.200.
Saleem Azad, M.D.	10 CFR 35.100 and 35.200.
Shameen Menon, M.D.	10 CFR 35.100 and 35.200.
Andre Knoski, M.D.	10 CFR 35.400.
Steven R. Miller, M.D.	10 CFR 35.400.
Jordan M. Maeir, M.D.	10 CFR 35.400.
Josephine J. Finazzo, D.O.	10 CFR 35.100 and 35.200.

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

- 14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application dated April 20, 2011; and
 - B. Letters dated September 12, 2011, March 19, 2013, March 4, 2014, July 18, 2014 and October 6, 2014.

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

By_

OCT 2 0 2014

Date

Bryan A. Parker

Materials Licensing Branch

Region III